天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Therapeutics and Clinical Risk Management >>article
Therapeutics and Clinical Risk Management

Therapeutics and Clinical Risk Management

IF: 2.79
Download PDF

Role of isavuconazole in the treatment of invasive fungal infections.

Published:3 August 2016 DOI: 10.2147/TCRM.S90335 PMID: 27536124
Dustin T Wilson, V Paul Dimondi, Steven W Johnson, Travis M Jones, Richard H Drew

Abstract

Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal infections continues to rise. Available antifungal agents to treat invasive fungal infections include polyenes, triazoles, and echinocandins. Unfortunately, individual agents within each class may be limited by spectrum of activity, resistance, lack of oral formulations, significant adverse event profiles, substantial drug-drug interactions, and/or variable pharmacokinetic profiles. Isavuconazole, a second-generation triazole, was approved by the US Food and Drug Administration in March 2015 and the European Medicines Agency in July 2015 for the treatment of adults with invasive aspergillosis (IA) or mucormycosis. Similar to amphotericin B and posaconazole, isavuconazole exhibits a broad spectrum of in vitro activity against yeasts, dimorphic fungi, and molds. Isavuconazole is available in both oral and intravenous formulations, exhibits a favorable safety profile (notably the absence of QTc prolongation), and reduced drug-drug interactions (relative to voriconazole). Phase 3 studies have evaluated the efficacy of isavuconazole in the management of IA, mucormycosis, and invasive candidiasis. Based on the results of these studies, isavuconazole appears to be a viable treatment option for patients with IA as well as those patients with mucormycosis who are not able to tolerate or fail amphotericin B or posaconazole therapy. In contrast, evidence of isavuconazole for invasive candidiasis (relative to comparator agents such as echinocandins) is not as robust. Therefore, isavuconazole use for invasive candidiasis may initially be reserved as a step-down oral option in those patients who cannot receive other azoles due to tolerability or spectrum of activity limitations. Post-marketing surveillance of isavuconazole will be important to better understand the safety and efficacy of this agent, as well as to better define the need for isavuconazole serum concentration monitoring.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Posaconazole 171228-49-2 C37H42F2N8O4 721 suppliers $6.00-$2691.10
Voriconazole 137234-62-9 C16H14F3N5O 687 suppliers $9.00-$2250.00
Amphotericin B 1397-89-3 C47H73NO17 624 suppliers $7.00-$27250.00
Isavuconazole 241479-67-4 C22H17F2N5OS 340 suppliers $15.00-$1800.00

Similar articles

IF:2.3

Isavuconazole: A New Option for the Management of Invasive Fungal Infections.

Annals of Pharmacotherapy Natasha N Pettit, Peggy L Carver,etc Published: 1 July 2015
IF:13

Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis

Drugs M. Shirley,?L. Scott,etc Published: 20 October 2016
IF:13

Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Drugs Susan J Keam, Katherine F Croom,etc Published: 1 January 2005